Jove
Visualize
お問い合わせ
このページは機械翻訳されています。他のページは英語で表示される場合があります。View in English
  1. ホーム
  3. 研究分野
  5. 生物医学と臨床科学
  7. 心血管医学と血液学
  9. 心臓病 (心血管疾患を含む)
  11. 経皮冠動脈介入 (talos-ami) を受けている急性心筋梗塞の安定した患者におけるチカグレロからクロピドグレルへの非ガイドドエスカレーション:

経皮冠動脈介入 (TALOS-AMI) を受けている急性心筋梗塞の安定した患者におけるチカグレロからクロピドグレルへの非ガイドドエスカレーション:

Chan Joon Kim1, Mahn-Won Park2, Min Chul Kim3

  • 1Department of Internal Medicine, Division of Cardiology, Uijeongbu St Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea.

Lancet (London, England)
|October 10, 2021

関連する実験動画

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

5.4K
Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.1K
A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis
18:11

A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis

Published on: December 28, 2012

24.4K

PubMed で要約を見る

まとめ
この要約は機械生成です。

急性心筋梗塞の後にチカグレロからクロピドグレルに切り替えると,出血のリスクが著しく低下します. この二重抗血小板療法戦略は,標準治療と比較して,純臨床イベントの減少に劣らず優れていることが示されました.

科学分野:

  • 心臓病科
  • 薬理学について
  • 臨床試験

背景:

  • 治療期間中に強力な抗血小板治療を受けている急性心筋梗塞の患者では高出血リスクが持続する.
  • チカグレロからクロピドグレルへの二重抗血小板療法 (DAPT) は,このリスクを軽減するための潜在的な戦略です.

研究 の 目的:

  • 急性心筋梗塞の後にチカグレロからクロピドグレルへのDAPTの統一された非誘導減圧戦略の有効性と安全性を評価する.
  • 標準のDAPT (チカグレロとアスピリン) と比較する

主な方法:

  • 経皮冠動脈干渉後の急性心筋梗塞 (PCI) の患者を対象とした無作為化非劣等性試験 (TALOS- AMI)
  • 患者をランダムに1対1で減量 (クロピドグレルとアスピリン) またはアクティブコントロール (ティカグレルとアスピリン) に割り当てました.
  • 主要エンドポイントは,心血管死,心筋梗塞,脳卒中,または1〜12ヶ月間のBARC出血でした.

主要な成果:

  • デエスカレーション群では,プライマリエンドポイントの発生率が有意に低かった (4. 6% vs 8. 2%,p< 0. 001),非劣等性と優位性 (HR 0. 55) を示した.
  • 心血管疾患による死亡,心筋梗塞,脳卒中) の複合的な症例の有意な差異は観察されなかった (2. 1% vs 3. 1%,p=0. 15).
  • BARCの出血は,減量群では著しく減少した (3. 0% 対 5. 6% , p=0. 0012).

結論:

  • 安定した急性心筋梗塞の患者では,チカグレロからクロピドグレルへの統一された非誘導的減速戦略は安全で有効です.
  • この戦略は,PCI後12ヶ月までの間,主に出血の減少によって,臨床イベントを大幅に減少させます.

関連する実験動画

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

5.4K
Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.1K
A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis
18:11

A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis

Published on: December 28, 2012

24.4K

関連する概念動画

Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

52
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
52
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

64
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
64
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

132
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
132
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

753
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
753
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

46
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
46
Angina IV: Management01:26

Angina IV: Management

50
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
50
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー